{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T10:54:38Z","timestamp":1775818478092,"version":"3.50.1"},"reference-count":52,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>There are limited data on discontinuation rates of antipsychotic medications (APMs) used to treat delirium due to acute hospitalization in the routine care of older adults.<\/jats:p><\/jats:sec>Objective<\/jats:title>To investigate discontinuation rates and patient characteristics of APMs used to treat delirium following infection-related hospitalization among older US adults.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This retrospective cohort study was conducted using US claims data (Optum\u2019s deidentified Clinformatics Data Mart database) for January 1, 2004, to May 31, 2022. Patients were aged 65 years or older without prior psychiatric disorders and had newly initiated an APM prescription within 30 days of an infection-related hospitalization. Statistical analysis was performed on December 15, 2022.<\/jats:p><\/jats:sec>Exposures<\/jats:title>New use (no prior use any time before cohort entry) of oral haloperidol and atypical APMs (aripiprazole, olanzapine, quetiapine, risperidone, etc).<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcome was APM discontinuation, defined as a gap of more than 15 days following the end of an APM dispensing. Survival analyses and Kaplan-Meier analyses were used.<\/jats:p><\/jats:sec>Results<\/jats:title>Our study population included 5835 patients. Of these individuals, 790 (13.5%) were new haloperidol users (mean [SD] age, 81.5 [6.7] years; 422 women [53.4%]) and 5045 (86.5%) were new atypical APM users (mean [SD] age, 79.8 [7.0] years; 2636 women [52.2%]). The cumulative incidence of discontinuation by 30 days after initiation was 11.4% (95% CI, 10.4%-12.3%) among atypical APM users and 52.1% (95% CI, 48.2%-55.7%) among haloperidol users (P<\/jats:italic> &amp;lt; .001 for difference between haloperidol vs atypical APMs). We observed an increasing trend in discontinuation rates from 2004 to 2022 (5% increase [95% CI, 3%-7%] per year) for haloperidol users (adjusted hazard ratio, 1.05 [1.03-1.07]; P<\/jats:italic>\u2009&amp;lt;\u2009.001) but not for atypical APM users (1.00 [0.99-1.01]; P<\/jats:italic>\u2009=\u2009.67). Prolonged hospitalization and dementia were inversely associated with the discontinuation of haloperidol and atypical APMs.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>The findings of this cohort study suggest that the discontinuation rate of newly initiated APMs for delirium following infection-related hospitalization was lower in atypical APM users than in haloperidol users, with prolonged hospitalization and dementia as major associated variables. The discontinuation rate was substantially higher in recent years for haloperidol but not for atypical APMs.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.0063","type":"journal-article","created":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T16:01:12Z","timestamp":1676649672000},"page":"e230063","source":"Crossref","is-referenced-by-count":9,"title":["Antipsychotic Medication Use Among Older Adults Following Infection-Related Hospitalization"],"prefix":"10.1001","volume":"6","author":[{"given":"Yichi","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts"},{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M.","family":"Wilkins","sequence":"additional","affiliation":[{"name":"Division of Geriatric Psychiatry, McLean Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lily Gui","family":"Bessette","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cassandra","family":"York","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Wong","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kueiyu Joshua","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2023,2,17]]},"reference":[{"issue":"4","key":"zoi230007r1","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1093\/ageing\/afl005","article-title":"Occurrence and outcome of delirium in medical in-patients: a systematic literature review.","volume":"35","author":"Siddiqi","year":"2006","journal-title":"Age Ageing"},{"issue":"7598","key":"zoi230007r2","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1136\/bmj.39169.706574.AD","article-title":"Delirium in older people.","volume":"334","author":"Young","year":"2007","journal-title":"BMJ"},{"issue":"9934","key":"zoi230007r3","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1016\/S0140-6736(14)60994-6","article-title":"Delirium in elderly people\u2013authors\u2019 reply.","volume":"383","author":"Inouye","year":"2014","journal-title":"Lancet"},{"issue":"1","key":"zoi230007r4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.5770\/cgj.17.90","article-title":"Delirium, a symptom of UTI in the elderly: fact or fable? a systematic review.","volume":"17","author":"Balogun","year":"2013","journal-title":"Can Geriatr J"},{"issue":"11","key":"zoi230007r5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.29540","article-title":"Delirium in older patients with COVID-19 presenting to the emergency department.","volume":"3","author":"Kennedy","year":"2020","journal-title":"JAMA Netw Open"},{"key":"zoi230007r6","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.2147\/CIA.S315405","article-title":"Delirium and inflammation in older adults hospitalized for COVID-19: a cohort study.","volume":"16","author":"Forget","year":"2021","journal-title":"Clin Interv Aging"},{"issue":"7","key":"zoi230007r7","doi-asserted-by":"publisher","first-page":"485","DOI":"10.7326\/M19-1860","article-title":"Antipsychotics for treating delirium in hospitalized adults: a systematic review.","volume":"171","author":"Nikooie","year":"2019","journal-title":"Ann Intern Med"},{"issue":"1","key":"zoi230007r8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12916-020-01685-9","article-title":"Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations.","volume":"18","author":"Ostuzzi","year":"2020","journal-title":"BMC Med"},{"issue":"5","key":"zoi230007r9","first-page":"617","article-title":"Adverse effects of antipsychotic medications.","volume":"81","author":"Muench","year":"2010","journal-title":"Am Fam Physician"},{"issue":"4","key":"zoi230007r10","first-page":"276","article-title":"Behavioral disorders in dementia: appropriate nondrug interventions and antipsychotic use.","volume":"94","author":"Reese","year":"2016","journal-title":"Am Fam Physician"},{"issue":"11","key":"zoi230007r11","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1111\/jgs.13702","article-title":"American Geriatrics Society 2015 Updated Beers Criteria for potentially inappropriate medication use in older adults.","volume":"63","author":"American Geriatrics Society 2015 Beers Criteria Update Expert Panel","year":"2015","journal-title":"J Am Geriatr Soc"},{"issue":"7","key":"zoi230007r12","doi-asserted-by":"publisher","first-page":"ITC49","DOI":"10.7326\/AITC202010060","article-title":"Delirium.","volume":"173","author":"Mattison","year":"2020","journal-title":"Ann Intern Med"},{"issue":"8","key":"zoi230007r14","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1002\/pds.v26.8","article-title":"Evaluation of algorithms to identify delirium in administrative claims and drug utilization database.","volume":"26","author":"Kim","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"zoi230007r15","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1111\/jgs.2017.65.issue-6","article-title":"Adverse events associated with antipsychotic use in hospitalized older adults after cardiac surgery.","volume":"65","author":"Kim","year":"2017","journal-title":"J Am Geriatr Soc"},{"key":"zoi230007r16","doi-asserted-by":"publisher","DOI":"10.1177\/2150132720932012","article-title":"A case-control study: the impact of unintentional discrepancies and pharmacist discharge prescription review on 30-day hospital readmission.","volume":"11","author":"Elbeddini","year":"2020","journal-title":"J Prim Care Community Health"},{"issue":"3","key":"zoi230007r17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.7326\/0003-4819-138-3-200302040-00007","article-title":"The incidence and severity of adverse events affecting patients after discharge from the hospital.","volume":"138","author":"Forster","year":"2003","journal-title":"Ann Intern Med"},{"issue":"6","key":"zoi230007r18","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1111\/jgs.2013.61.issue-6","article-title":"Association between sedating medications and delirium in older inpatients.","volume":"61","author":"Rothberg","year":"2013","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"zoi230007r19","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/jgs.13943","article-title":"Antipsychotic use in hospitalized adults: rates, indications, and predictors.","volume":"64","author":"Herzig","year":"2016","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"zoi230007r20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/pds.v22.1","article-title":"The incident user design in comparative effectiveness research.","volume":"22","author":"Johnson","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"zoi230007r21","doi-asserted-by":"publisher","first-page":"S131","DOI":"10.1097\/MLR.0b013e318070c08e","article-title":"Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results.","volume":"45","author":"Schneeweiss","year":"2007","journal-title":"Med Care"},{"issue":"5","key":"zoi230007r22","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s41395-018-0039-2","article-title":"Chronic nausea and vomiting: evaluation and treatment.","volume":"113","author":"Lacy","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"zoi230007r23","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006938.pub3","article-title":"Droperidol for treatment of nausea and vomiting in palliative care patients.","volume":"2014","author":"Storrar","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"579","key":"zoi230007r24","doi-asserted-by":"publisher","first-page":"e385","DOI":"10.3399\/bjgp10X532396","article-title":"Pneumonia following antipsychotic prescriptions in electronic health records: a patient safety concern?","volume":"60","author":"Star","year":"2010","journal-title":"Br J Gen Pract"},{"issue":"8","key":"zoi230007r25","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1093\/gerona\/gly197","article-title":"Validation of a claims-based frailty index against physical performance and adverse health outcomes in the Health and Retirement Study.","volume":"74","author":"Kim","year":"2019","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"7","key":"zoi230007r26","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1093\/gerona\/glx229","article-title":"Measuring frailty in Medicare data: development and validation of a claims-based frailty index.","volume":"73","author":"Kim","year":"2018","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"6","key":"zoi230007r27","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/gerona\/glz224","article-title":"Measuring frailty in administrative claims data: comparative performance of four claims-based frailty measures in the U.S. Medicare data.","volume":"75","author":"Kim","year":"2020","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"7","key":"zoi230007r28","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1093\/gerona\/glaa150","article-title":"Updating International Classification of Diseases 9th Revision to 10th Revision of a claims-based frailty index.","volume":"76","author":"Gautam","year":"2021","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"7","key":"zoi230007r29","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2022.1812","article-title":"Cautions when using race and ethnicity in administrative claims data sets.","volume":"3","author":"Nead","year":"2022","journal-title":"JAMA Health Forum"},{"issue":"446","key":"zoi230007r31","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk.","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"10","key":"zoi230007r33","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1111\/jgs.15026","article-title":"Discharge plans for geriatric inpatients with delirium: a plan to stop antipsychotics?","volume":"65","author":"Johnson","year":"2017","journal-title":"J Am Geriatr Soc"},{"issue":"9","key":"zoi230007r34","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-052547","article-title":"Deprescribing intervention activities mapped to guiding principles for use in general practice: a scoping review.","volume":"11","author":"Coe","year":"2021","journal-title":"BMJ Open"},{"issue":"7","key":"zoi230007r35","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.sapharm.2020.09.005","article-title":"Deprescribing interventions in primary health care mapped to the Behaviour Change Wheel: a scoping review.","volume":"17","author":"Isenor","year":"2021","journal-title":"Res Social Adm Pharm"},{"issue":"3","key":"zoi230007r36","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1007\/s00134-003-2117-0","article-title":"Olanzapine vs haloperidol: treating delirium in a critical care setting.","volume":"30","author":"Skrobik","year":"2004","journal-title":"Intensive Care Med"},{"issue":"6","key":"zoi230007r37","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3109\/00048674.2011.543411","article-title":"Aripiprazole and haloperidol in the treatment of delirium.","volume":"45","author":"Boettger","year":"2011","journal-title":"Aust N Z J Psychiatry"},{"issue":"4","key":"zoi230007r38","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1017\/S1478951514001059","article-title":"Haloperidol, risperidone, olanzapine and aripiprazole in the management of delirium: a comparison of efficacy, safety, and side effects.","volume":"13","author":"Boettger","year":"2015","journal-title":"Palliat Support Care"},{"issue":"5","key":"zoi230007r39","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/(ISSN)1099-1557","article-title":"All-cause mortality associated with atypical and typical antipsychotics in demented outpatients.","volume":"16","author":"Trifir\u00f2","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"11","key":"zoi230007r40","doi-asserted-by":"publisher","first-page":"775","DOI":"10.7326\/0003-4819-146-11-200706050-00006","article-title":"Antipsychotic drug use and mortality in older adults with dementia.","volume":"146","author":"Gill","year":"2007","journal-title":"Ann Intern Med"},{"issue":"5","key":"zoi230007r41","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1503\/cmaj.061250","article-title":"Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients.","volume":"176","author":"Schneeweiss","year":"2007","journal-title":"CMAJ"},{"key":"zoi230007r43","doi-asserted-by":"publisher","first-page":"k1218","DOI":"10.1136\/bmj.k1218","article-title":"Use of haloperidol versus atypical antipsychotics and risk of in-hospital death in patients with acute myocardial infarction: cohort study.","volume":"360","author":"Park","year":"2018","journal-title":"BMJ"},{"issue":"3","key":"zoi230007r44","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/jgs.v68.3","article-title":"Antipsychotics and the risk of mortality or cardiopulmonary arrest in hospitalized adults.","volume":"68","author":"Basciotta","year":"2020","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"zoi230007r45","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1017\/S104161020300958X","article-title":"Incidence of delirium, risk factors, and long-term survival of elderly patients hospitalized in a medical specialty teaching hospital in Mexico City.","volume":"15","author":"Villalpando-Berumen","year":"2003","journal-title":"Int Psychogeriatr"},{"issue":"1","key":"zoi230007r46","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/S1036-7314(05)80019-0","article-title":"Multicentre study of delirium in ICU patients using a simple screening tool.","volume":"18","author":"Roberts","year":"2005","journal-title":"Aust Crit Care"},{"issue":"3","key":"zoi230007r47","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.ccc.2017.03.013","article-title":"Acute brain failure: pathophysiology, diagnosis, management, and sequelae of delirium.","volume":"33","author":"Maldonado","year":"2017","journal-title":"Crit Care Clin"},{"issue":"1","key":"zoi230007r48","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12916-017-0899-0","article-title":"Epidemiology and outcomes of people with dementia, delirium, and unspecified cognitive impairment in the general hospital: prospective cohort study of 10,014 admissions.","volume":"15","author":"Reynish","year":"2017","journal-title":"BMC Med"},{"issue":"17","key":"zoi230007r49","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1001\/archinternmed.2012.3203","article-title":"Delirium and long-term cognitive trajectory among persons with dementia.","volume":"172","author":"Gross","year":"2012","journal-title":"Arch Intern Med"},{"issue":"1-2","key":"zoi230007r50","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1159\/000485794","article-title":"Risk factors and outcomes of delirium in older patients admitted to postacute care with and without dementia.","volume":"45","author":"Gual","year":"2018","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"11","key":"zoi230007r51","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1111\/jgs.13791","article-title":"Partial and no recovery from delirium in older hospitalized adults: frequency and baseline risk factors.","volume":"63","author":"Cole","year":"2015","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"zoi230007r52","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1001\/jamainternmed.2016.7491","article-title":"Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial.","volume":"177","author":"Agar","year":"2017","journal-title":"JAMA Intern Med"},{"key":"zoi230007r13","unstructured":"Optum. Clinformatics Data Mart. Accessed December 14, 2022. https:\/\/www.optum.com\/content\/dam\/optum\/resources\/productSheets\/Clinformatics_for_Data_Mart.pdf"},{"key":"zoi230007r30","unstructured":"Gray? B. cmprsk: subdistribution analysis of competing risks. R package version 2.2-11. 2022. Accessed December 14, 2022. https:\/\/cran.r-project.org\/web\/packages\/cmprsk\/index.html"},{"key":"zoi230007r32","unstructured":"Aetion Inc. Aetion Evidence Platform: software for real-world data analysis. 2020. Accessed December 14, 2022. https:\/\/aetion.com"},{"key":"zoi230007r42","unstructured":"US Food and Drug Administration. Information for healthcare professionals: conventional antipsychotics. Updated August 15, 2013. Accessed December 14, 2022. https:\/\/wayback.archive-it.org\/7993\/20170722190727\/https:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm124830.htm"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2801581\/zhang_2023_oi_230007_1675954460.68593.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T16:01:19Z","timestamp":1676649679000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2801581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,17]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.0063","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,17]]}}}